Sheep erythrocytes coated with three monoclonal antibodies, each reactive td a different epitope of the 66-kilodalton cytomegalovirus (CMV) matrix protein, were used in a reverse passive hemagglutination test with CA V-infected cell lysate to identify and confirm the CMV. The test is specific only for CMV, since 5 laboratory striins of CMV (AD169, Davis, Espilat, C-87, and Towne) and 10 clinical isolates reacted well, but uninfected MRC-5 cell lysate, lysates of herpes simplex virus types 1 and 2, varicella-zoster virus, and adenoviruses did not react. The reactive CMV lysate was confirmed by the pretreatment of CMV lysate with the three monoclonal antibodies followed by the addition of antibody-coated erythrocytes. The reverse passive hemagglutination test and the confirmatory blocking test are performed at the same time, requiring 2 h to comiplete. Since V-bottom microtiter 96-well plates and a 25-,u pipette can be used to perform the test, it is ideal for CMV confirmation, especially when the equipment to read the fluorescent-antibody test or enzyme-linked immunosorbent assay is not available.
Human, cytomegalovirus (CMV) has been implicated in various disease syndromes in humans, some of which have serious consequences, particularly for newborns (1-7, 14, 16-18) . Rapid diagnosis of CMV infection is important in the treatment and management of these patients. Because of the lack of a simple method that does not require expensive instruments, a small laboratory relies on the recognition of a specific type of viral cytopathic effect which develops slowly (days to weeks) in suitable human emnbryonic fibroblast cells inoculated with clinical specimens. Recently, Shuster et al. (15) reported Sn elegant and sensitive way to detect CMV, but many small laboratories are not able to conduct sedimentation inoculation followed by the indirect immunofluorescent-antibody test with monoclonal antibody reactive to CMV early protein. We reported the successful production of murine monoclonal antibodies to a CMV, major glycosylated protein with a molecular weight of 66,000 (GP-66) (13) . GP-66 represents 20 to 35% of the tOtal protein in purified CMV and dense bodies (12) . To develop a simpler and less expensive method, the cell agglutination method first reported by Juji and Yokochi (10) , which has sensitivity close to that of the enzyme immunoassay or the radioimmunoassay, was adopted for the detection of human CMV. We used a mixture of three GP-66-reactive monoclonal antibodies The micro-CF method described by Waner et al. (19, 20) was used. The endpoint was the highest dilution that gave 75% (3+) fixation, which was determined by the amount of sheep erythrocytes sedimented in the presence of a constant amount of human reference serum to human CMV obtained from M.A. Bioproducts, Walker, Md. Antibody-coated erythrocytes were made 3% with goat serum and 4% with either lactose, mannitol, or sucrose, quick-frozen in liquid nitrogen, and lyophilized overnight. The sensitized erythrocytes were suspended in PBS and used.
To obtain the maximal absorbtion of the antibodies by the erythrocytes, several different pHs (3.0, 4.0, 4.6, and 5.0) of acetate buffer were used to coat the antibodies to the erythrocytes. At pHs 3.0 and 4.0, the control antigen gave a nonspecific reaction; therefore, at these pHs we were unable to determine the hemagglutination (HA) titer of the CMV CF antigen. However, at pHs 4.6 and 5.0, the control CF antigen showed an HA titer of <1:2, whereas the CMV CF antigen showed titers of 1:128 and 1:32, respectively. Therefore, the optimal combination of sensitivity with a nonreactive control pattern (HA titer of <1:2) was obtained with pH 4.6 acetate buffer.
Three concentrations of antibody (0.25, 0.5, and 1 mg/ml) were used to coat the erythrocytes for 60 and 120 min. A concentration of 0.25 mglml gave an HA titer of 1:64 with CMV CF antigens, whereas concentrations of 0.50 and 1.00 mg/ml both gave HA titers of 1:128. Maximum titers were obtained at 60 min; no further increase was achieved with an additional 60-min incubation. Control CF antigen had an HA titer of <1:2 at all antibody concentrations. Therefore, the optimal conditions for the sensitization of the erythrocytes used were as follows. Samples (1-ml) of 10% (vol/vol) glutaraldehyde-treated cells were washed once with 0.1 M sodium acetate (pH 4.6). The sedimented cells were suspended in 1 ml of a mixture of the three monoclonal antibodies (each 1 mg/3 ml). The erythrocyte suspension was put on a rotary shaker at room temperature for 1 h. The cells were then washed and processed as described above.
The antibody-sensitized erythrocytes were suspended at various concentrations (0.1, 0.2, and 0.5%) and were added to twofold serial dilutions of CMV antigen prepared in Dynatech V-bottom microtiter plates. The best patterns of agglutination and ease of reading occurred with an erythrocyte concentration of 0.2%. The tests were readily readable in 2 h at room temperature. After 18 h at room temperature, cell patterns were occasionally more distinct, but the titers remained the same. HA titers for all these erythrocyte concentrations were the same.
To determine how soon p.i. the CMV RPHA test system would detect the synthesis of GP-66, a time course experiment was done. Monolayers of MRC-5 were infected at a multiplicity of infection of 3 PFU with CMV strain AD169. After 2 h of virus absorption at 37°C, cells were washed three times with growth medium, and then growth medium was added. At different times p.i. (0, 24, 48, 72, 96, and 144 h), the amount of antigen in the infected cell lysate was tested by using the sensitized erythrocytes. GP-66 was detected in the infected cell lysates from 24 h p.i., when the HA titer was 1:2, as opposed to <1:2 at time zero. The HA titer steadily increased with time to a maximum HA titer of 1:128 at 144 h p.i. An The effect of storage conditions on the stability of the coated erythrocytes as determined by the HA titer was studied. Antibody-coated erythrocytes (0.2%) were stored at 4°C. In addition, a 2% suspension was lyophilized under various conditions and stored at 4°C. The sensitized erythrocytes at 4°C were stable for at least the 15 days tested (Table 1) . When a 2% erythrocyte suspension in PBS was lyophilized and suspended in either deionized water or PBS to 0.2% erythrocytes, nonspecific agglutination occurred. When a 2% erythrocyte suspension was lyophilized in the presence of 3% goat serum, 4% sucrose, or 4% sucrose plus 3% goat serum and reconstituted in deionized water or PBS, nonspecific agglutination did not occur, and the cells were very stable, i.e., the HA titer remained unchanged for the 15 days tested at 4°C.
The specificity of the assay was evaluated by testing various laboratory strains of CMV and several clinical CMV isolates which were confirmed by an indirect fluorescentantibody test with GP-66-specific monoclonal antibody. All the laboratory CMV strains and clinical isolates showed a positive HA pattern after 2 h at room temperature. The relative CMV antigen titer varied from strain to strain and from one isolate to another (Table 2 ). This was a reflection of the different degree of cytopathic effect and the amount of CMV antigen accumulated at the time of harvest and not strain or isolate variations (11) . This was evidenced by the amount of CF antigen present in the samples. In previous experiments, we showed that the antigen titer detected by monoclonal antibodies to GP-66 was always directly proportional to infectivity for all the CMV strains we tested (data not shown). We also showed that 1 U of human CMV CF antigen is equivalent to approximately 107 PFU (K. S. Kim, C. Juneja, V. J. Sapienza, and K. Wisniewski, Abstr. Annu. Meet. Am. Soc. Microbiol. 1982, S49, p. 243). The results presented in Table 2 clearly show that sensitized erythrocytes gave a titer much higher than the titer obtained by the CF test in 2 h at room temperature.
The performance of the confirmatory blocking test is shown in Table 2 . Endpoint titers for laboratory strains and the 10 clinical isolates were reduced to <1:2 when dilutions of CMV CF antigen preparations were tested on the sensitized erythrocytes in anti-CMV-containing diluent. The blocking test for only three clinical isolates is shown in Table   2 .
The primary focus of this study was to investigate the use of the RPHA for the detection of CMV antigen for a possible application to CMV confirmation in clinical virology. To achieve this objective, three monoclonal antibodies against GP-66, a major glycosylated peptide of CMV, were used for sensitization of sheep erythrocytes, and the sensitized erythrocytes were used for the detection of CMV in infected lysates. These three monoclonal antibodies are reactive to different epitopes on GP-66 and are also reactive to GP-66 even after sodium dodecyl sulfate treatment, as shown by immunoblotting (13) . These antibodies are reactive, therefore, to very stable epitopes on the CMV virion, which makes them very suitable for use in detecting clinical laboratory isolates. In addition, we showed that antibody-coated erythrocytes are stable for at least' 15 days both as a suspension and when lyophilized with stabilizers, which 
